ROCKVILLE, Md.--(BUSINESS WIRE)--
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty
pharmaceutical company, today announced that the Company's management
will be hosting investor meetings during Citi's 2014 Global Healthcare
Conference.
Date: Tuesday, February 25
Place: The Hilton New York Hotel
Investors interested in arranging a meeting during this conference
should contact their Citi representative.
Supernus also announced that management will provide a business update
on the Company at the 2014 RBC Capital Markets Global Healthcare
Conference.
Date: Wednesday, February 26
Presentation Time: 9:00am ET
Place:
The New York Palace, New York, NY
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company
focused on developing and commercializing products for the treatment of
central nervous system, or CNS, diseases. The Company has two marketed
products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and
Trokendi XR™ (extended-release topiramate). The Company is also
developing several product candidates in psychiatry to address large
market opportunities in ADHD, including ADHD patients with impulsive
aggression. These product candidates include SPN-810 for impulsive
aggression in ADHD and SPN-812 for ADHD.
Supernus Pharmaceuticals, Inc.
Jack A. Khattar, President and CEO
Gregory
S. Patrick, Vice President and CFO
301-838-2591
or
Investor
Contact:
Cockrell Group
877-889-1972
investorrelations@thecockrellgroup.com
cockrellgroup.com
Source: Supernus Pharmaceuticals, Inc.
News Provided by Acquire Media